The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review

Rubis, Anton; Juodžbalys, Gintaras

doi:10.5037/jomr.2020.11202

Cited by 17 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the grounds of this report it can be concluded that BTX-A might be useful in 70% of patients with TN. [53,54] Increasing evidence confirms that BTX-A injection is efficient and may be particularly useful in the treatment of patients before surgery or patients who are unwilling to undergo more invasive procedures. [6] The efficiency of Botulinum toxin treatment is determined on the basis of the guidelines of the American Academy of Neurology.…”

Section: Botulinum Injectionsmentioning

confidence: 99%

See 1 more Smart Citation

Trigeminal Neuralgia - where are we today?

Perszke

Egierska

Martynowicz

2022

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Trigeminal neuralgia (TN) is one of the most crippling facial pain syndromes, which has a significant impact on quality of life. This chronic disorder presents as brief shock-like paroxysmal severe, stabbing pain with rapid onset in the distribution of trigeminal nerve (CNV). The aim of this article was to review the recent literature about the epidemiology, pathogenesis, diagnosis, treatment methods and the important advances in all these fields.Etiology and pathomechanism: The best known and tested theory on the genesis of the trigeminal neuralgia seems to be a nerve compression at the nerve root entry-zone. However there are other theories like the trigeminal convergence-projection theory, the bioresonance hypothesis or the ignition theory that are trying to explain the etiology of TN. Treatment: Available treatment methods consist mainly of medications and surgical procedures. Surgical treatment may be divided into 2 categories: destructive and non-destructive. Among these interventions we can distinguish percutaneous rhizotomy stereotactic radiosurgery and microvascular decompression. All of them are very efficacious, however MVD is approved as the gold standard in the treatment of TN. Botulinum neurotoxin type A injections are not the first line for treatment, but it may be an attractive alternative for classic pharmaceutical or surgical therapy, as it’s safe and effective. Acupuncture is also proposed in recent studies as a valuable treatment option, even though there is little well-designed research.Conclusion: Much remains to be learned about the diagnosis, pathomechanism and methods of treatment of neuropathic pain and the efficacy of each of them. Further evidence-based studies are needed, as the amount of reliable materials is still not sufficient and lots of them have yet to be examined.

show abstract

Section: Botulinum Injectionsmentioning

confidence: 99%

“…The other conditions resolved in 1 week. [53] BTX-A injection is a promising therapeutic strategy for treatment of TN. According to recent studies this type of therapy is safe and efficacious for patients with classical as well as drug-resistant idiopathic trigeminal neuralgia.…”

Section: Botulinum Injectionsmentioning

confidence: 99%

Trigeminal Neuralgia - where are we today?

Perszke

Egierska

Martynowicz

2022

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…Current studies have shown that BTX-A is an effective and safe treatment for trigeminal neuralgia (Ostrowski et al, 2009a;Rubis & Juodzbalys, 2020). A recent study examining factors influencing the efficacy on BTX-A found that a higher success rate of BTX-A treatment was observed in patients aged 50 years or older, but the age factor did not make a significant difference in the time to recurrence of pain, the onset of effect, or peaktime after BTX-A treatment (Wu et al, 2019).…”

Section: Trigeminal Neuralgiamentioning

confidence: 99%

Advances in botulinum toxin type A for the treatment of pain

Jiang¹,

Huang²,

Yang³

et al. 2021

NRFHH

View full text Add to dashboard Cite

<i>Clostridium botulinum</i> (CB) is a Gram-positive anaerobic bacterium and a significant cause of food spoilage. Foodborne botulism occurs worldwide every year and even lead to death from respiratory distress in severe cases after eating botulism-contaminated food. The pathogenicity of CB lies in its ability to produce a potent neurotoxin, “botulinum toxin (BTX)”, for which eight different subtypes have already been isolated so far. Botulinum toxin type A (BTX-A) is widely used to treat critical clinical issues due to its good affinity and tolerability. Studies have shown that BTX-A injections effectively treat myofascial pain, inflammatory pain, and neuropathic pain. The current article mainly reviews the latest research progress using BTX-A in pain treatment during two years.

show abstract

“…The use of BTA in trigeminal neuralgia is supported by four positive RDBPC trials, which included a total of 178 patients, although a recent meta-analysis suggested the quality of most of these trials was poor [ 52 ]. BTA is an option for patients if standard medications are not effective enough or not tolerated, or if surgery is not an option or unsuccessful.…”

Section: Other Headache Typesmentioning

confidence: 99%

Botulinum Toxin in the Treatment of Headache

Becker

2020

Toxins

View full text Add to dashboard Cite

Botulinum toxin type A has been used in the treatment of chronic migraine for over a decade and has become established as a well-tolerated option for the preventive therapy of chronic migraine. Ongoing research is gradually shedding light on its mechanism of action in migraine prevention. Given that its mechanism of action is quite different from that of the new monoclonal antibodies directed against calcitonin gene-related peptide (CGRP) or its receptor, it is unlikely to be displaced to any major extent by them. Both will likely remain as important tools for patients with chronic migraine and the clinicians assisting them. New types of botulinum toxin selective for sensory pain neurons may well be discovered or produced by recombinant DNA techniques in the coming decade, and this may greatly enhance its therapeutic usefulness. This review summarizes the evolution of botulinum toxin use in headache management over the past several decades and its role in the preventive treatment of chronic migraine and other headache disorders.

show abstract

The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review

Cited by 17 publications

References 35 publications

Trigeminal Neuralgia - where are we today?

Trigeminal Neuralgia - where are we today?

Advances in botulinum toxin type A for the treatment of pain

Botulinum Toxin in the Treatment of Headache

Contact Info

Product

Resources

About